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Guillain-Barré syndrome: causes, immunopathogenic mechanisms and treatment
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ABSTRACT
10 Introduction: Guillain-Barrè syndrome is a rare disease representing the most frequent cause of acute
flaccid symmetrical weakness of the limbs and areflexia usually reaching its peak within a month. The
etiology and pathogenesis remain largely enigmatic and the syndrome results in death or severe
disability in 9–17% of cases despite immunotherapy.
Areas covered: In terms of etiology, Guillain-Barrè syndrome is linked to Campylobacter infection but
15 less than 0.1% of infections result in the syndrome. In terms of pathogenesis, activated macrophages
and T cells and serum antibodies against gangliosides are observed but their significance is unclear.
Expert commentary: Guillain-Barrè syndrome is a heterogeneous condition with numerous subtypes
and recent data point towards the role of ganglioside epitopes by immunohistochemical methods.
Ultimately, we are convinced that the syndrome results from a permissive genetic background on which
20 environmental factors, including infections, vaccination and the influence of aging, lead to disease.
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1. Introduction
Guillain–Barré syndrome (GBS) represents the most common
cause of acute flaccid symmetrical weakness of the limbs and
areflexia in the post-polio era. In general terms, GBS encom-
25 passes a wide range of clinical syndromes with an acute inflam-
matory polyradiculoneuropathy, muscle weakness, and reduced
reflexes. It was first described almost 100 years ago by three
French neurologists Georges Guillain, Jean-Alexandre Barré, and
Andre Strohl in two soldiers with elevated protein concentra-
30 tion and a normal cell count in the cerebrospinal fluid (CSF). In
1949, Haymaker and colleagues described the clinicopathologic
features of 50 fatal GBS cases and noted axonal degeneration,
myelin breakdown, and nerve edema [1]. In 1986, Feasby and
colleagues further described a GBS variant with predominant
35 direct axonal damage rather than demyelination [2], which was
later coined acute motor axonal neuropathy (AMAN) or acute
motor sensory neuropathy (AMSAN), secondary to the molecu-
lar mimicry between bacterial lipooligosaccharide and the
human GM1AQ2 ganglioside [3–5]. Based on these observations
40 and the proposed role for autoimmunity, intravenous immuno-
globulin (IVIg) and plasma exchange are utilized in GBS [6],
without impacting on the risk of death or severe disability
which ensues in 9–17% of cases [7].
Along with enormous progress made in the understanding of
45   immune-mediated neurological disorders [8,9], particularly multi-
ple sclerosis [10–13], the past 10 years have witnessed substantial
advancements in the epidemiology, immunopathogenesis,
clinical features, and clinical management of GBS, and this manu-
script will provide a comprehensive overview of the past and
50recent lines of evidence. This is well illustrated by the fact of
serum antiganglioside antibodies, often detected although their
levels decrease over time [14], which may represent a good
candidate biomarker in this complex condition, despite their
limited sensitivity particularly in patients with AMAN and virtual
55absence in acute inflammatory demyelinating polyradiculoneuro-
pathy (AIDP) [15].
2. Epidemiology
The term GBS can be used to denote a syndrome that includes
the aforementioned AMAN, the  AIDP  and other variants such as
60AMSAN, and the Miller-Fisher syndrome (MFS), which is char-
acterized by ataxia, ophthalmoplegia, and areflexia. Overall, the
clinical course, severity, and outcomes of GBS are highly vari-
able. However, with the identification of several new pheno-
types in the past years, the conceptual framework of GBS has
65become increasingly complex.
The incidence of typical GBS ranges between 0.81 and 1.89
(median 1.11) cases per 100,000   person-years, being more
common in men than women (sex ratio 1.5  :1), and available
data are illustrated in Table 1. The prevalence and incidence of
70GBS increase  with age, and age-specific GBS rates are 0.62
cases per 100,000 person  -years among 0–9  -  year-old subjects
versus 2.66 cases per 100,000 person-years in the 80–  89-  year-
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old population [16]. The crude incidence rate ofAQ3 GBS in
Bangladesh was highest (2.5 per 100,000 person-years)  with
75 seasonal fluctuation and a peak in May [17] and lowest (0.40
per 100,000 person-years) in Brazil [18]. The epidemiology of
the AMAN subphenotype of GBS is limited, and the reported
frequency using electrodiagnostic criteria is highest (65%) in
Chinese patients [19] compared to 6–7% in North American
80 and European series [20,21]. It has been hypothesized that
AMAN is more prevalent with poor hygiene infrastructures
and higher incidence of diarrhea [22]. The severity of GBS
cases also manifests different prevalence rates in different
areas being highest in China compared to Europe and the
85 USA, particularly in cases of AMAN group and Bickerstaff’s
brain stem encephalitis requiring mechanical ventilation with
the former representing 4% of GBS cases in Japan, 6% in India,
and 11% in Bangladesh [22].
3. Prior infections
90 Over  two-thirds of patients with GBS refer symptoms of respira-
tory or digestive infections within  6 weeks of onset [22,35]. In
30–40% of GBS cases, Campylobacter is the infecting agent, and
it has been estimated that 1/1058 infections results in GBS [36].
The association between GBS and Campylobacter  jejuni was first
95 described around 1982 in clinical anecdotes by Rhodes and
Tatterfield [37]. Other infections preceding GBS may derive
from Mycoplasma pneumoniae, Haemophilus influenzae,
Salmonella species, Mycobacterium bovis, Brucella, Orientia tsut-
sugamushi, Legionella pneumophila, Bartonella henselae,
100 Helicobacter pylori, Francisella tularensis, Borrelia, cytomegalo-
virus, Epstein–Barr virus, varicella-zoster virus, influenza virus,
human immunodeficiency virus, parainfluenza virus type 1,
adenovirus, herpes simplex virus, hepatitis (A, B, and E),
Japanese encephalitis virus, West Nile virus, enterovirus (D68,
105 71), Hantavirus, measles, Parvovirus B19, Norovirus, parecho-
virus, Coxsackieviruses, Echovirus, mumps, rubella, polio (wild-
type 3), dengue, chikungunya, and Zika viruses [37–41]  (for
details, see Table 2). Several vaccines, including influenza A
H1N1, rabies, meningococcal, live-attenuated yellow fever,
110 hepatitis A and B, smallpox, polio, MMR, tetanus–diphtheria,
and   H.  influenzae type B, have also been considered as a
possible trigger of GBS [42,43].
AQ4
The Zika virus is a mosquito-borne flavivirus [140] that was
first observed in 1947 and was demonstrated in numerous
115 cases since 2007 [141] with a most recent outbreak in
numerous countries worldwide [142]. Zika virus infection has
been linked to GBS as cases have been reported within a Zika
and Dengue fever epidemics in French Polynesia [127], but it
remains unclear which infection was related to the neurologi-
120cal manifestations, as previous reports suggested a connection
with Dengue fever. The mechanisms involved would be that of
molecular mimicry, which can exist on  a primary amino acid
basis, secondary, or even tertiary structure [128].
Molecular mimicry is an important mechanism that can
125lead to autoimmune responses, and further data on not only
vaccination  but also infection  will require the ability to do
detailed analysis of the structural homologies and the indivi-
dual host immune response. Certain criteria need to be met
before attributing disease causation to molecular mimicry.
130These include  epidemiological evidence linking the suspected
infectious agent or exogenous substance with the autoim-
mune disease; identification of T-cell responses or specific
antibodies against the target autoantigen; identification of
structural homology between the infectious agent or exogen-
135ous substance and the target autoantigen; and finally, repro-
duction of the autoimmune disease following immunization
with the infectious agent or exogenous substance in an animal
model [143]. The axonal subphenotype of GBS is the only
autoimmune disease at present that fulfills all four criteria for
140molecular mimicry [144]. Other mechanisms explaining the
relationship between infection and GBS may include epitope
spreading, bystander activation, the production of super  anti-
gens, and aberrant activation of the immune response [145].
4. Pathogenesis
145Different mechanisms are proposed for AIDP and  AMAN. In the
former case, Asbury et al. in 1969 first reported the segmental
demyelination restricted to nerve regions infiltrated by T cells
and macrophages in  four patients who died from GBS [146].
This led to the understanding that myelin damage is caused
150predominantly by activated macrophages which penetrate the
basement membrane around nerve fibers ultimately leading
to demyelination [147]. Furthermore, patients with acute GBS
have lower peripheral CD4+ CD25+ T-cell count compared to
controls, thus also supporting the role of T cells in pathogen-
155esis of GBS [148]. The demonstration of complement activa-
tion products on the surface of Schwann cells and the
identification of vesicular myelin degeneration led to hypoth-
esis that complement activation on Schwann cell surface led
to demyelination. The complement activation was mediated
160by the binding of specific antibodies to epitopes on the
Schwann cell surface followed by vesiculation of myelin before
invasion of macrophages [149]. The invasion of Schwann cell
basement membrane was hypothesized to be a consequence
of the increased matrix metalloproteinase 9 (MMP9) observed
165in patients with GBS [44]. Macrophages target antigens on the
surface of Schwann cells or myelin sheath via activated T cells
and MMP9 along with toxic nitric oxide radicals released by
activated macrophages lead to Schwann cell injury and sub-
sequent invasion of the peripheral nerve [150]. Furthermore,
170the inflammatory mediators and cells may induce axonal
damage in severe cases of AIDP in a process referred to as
secondary degeneration [150]. Nonetheless, we should also
Table 1. Reported incidence rates of Guillain–Barré syndrome in different
Countries [16].
Author Reference N Yearly incidence (/100,000) Country
Deceuninck [23] 33 0.81 Canada
Winner and Evans [24] 72 1.1 England
Govoni [25] 69 1.89 Italy
Bogliun and Beghi [26] 138 1.55 Italy
Chiò [27] 126 1.44 Italy
Sedano [28] 63 1.03 Spain
Aladro-Benito [29] 81 1.04 Spain
Cuadrado [30] 337 0.85 Spain
Cuadrado [31] 98 1.25 Spain
Cheng [32] 73 1.63 Sweden
Beghi [33] 48 1.68 USA
Schonberger [34] 418 0.94 USA
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Table 2. The proposed links between Guillain–Barré syndrome and infection, from C. jejuni to Zika virus.
Agent Epidemiology
Subphenotype(s)
association
Physiopathological
mechanism Pathogen characteristics
Anti-gangliosides
antibodies References
Bacterial
Campylobacter
jejuni
C. jejuni has consistently
been identified as the
most frequent
antecedent infection in
GBS, appearing in
approximately a quarter
of patients
Predominantly,
but not
exclusively,
related to
AMAN
Molecular mimicry: cross-
reactivity between
epitopes on C. jejuni
and peripheral nerve
gangliosides
C. jejuni epitopes: surface
LOS, subtyping into
seven classes (A–G)
based on the presence
of specific LOS loci
AMAN: anti-GM1a, GM1b,
GD1a, and GalNAc-
GD1a gangliosides
[6,44–52]
GBS following C.
jejuni infection
may be more
severe than that
caused by other
infectious
agents
Ganglioside expression is
tissue-specific and anti-
ganglioside profiles,
therefore determine
patterns of neurological
involvement
Class A (GBS) and B
(MFS) locus
MFS or MFS–GBS overlap
syndrome: anti-GD1b,
GD3, GT1a, and GQ1b
gangliosides
Polymorphisms: cstII
gene, Thr51 variant
(GBS), Asn51 variant
(MFS), TNF, and MBL2
gene
MFS and BBE: anti-GT1a
and GQ1b
Approximately 1  in 1000
patients with C. jejuni
goes on to develop GBS
Complement activation
seems to contribute to
nerve degeneration in
GBS
C. jejuni serotypes O:19
(GBS), O:2 (FS)
Antibodies against
combinations of
epitopes from
ganglioside complexes
C. jejuni LPO bind to
siglec-7 (sialic acid 
binding
immunoglobulin-like
lectin 7) and activate
dendritic cells via Toll-
like receptor 4 and
CD14. These dendritic
cells produce type 1
interferon and  TNF,
which induce
proliferation of B cells
C. jejuni subspecies  jejuni
HS:41 strains RM3196
(233.94) and RM3197
(308.95)
Mycoplasma
pneumoniae
M. pneumoniae
seropositivity in GBS
patients ranges
significantly (1–25%)
AIDP, BBE, MFS Molecular mimicry Presence of GM1 epitope
in M. pneumoniae.
Anti-GM1 (pathogenic),
Gal-C (possible
epiphenomenon), and
GA1
[53–56]
Haemophilus
influenzae
H. influenzae is a normal
constituent of upper
respiratory tract flora in
80% of humans, and
isolation may occur in
conjunction with other
infectious triggers of
GBS
MFS and AIDP Molecular mimicry Of the six serotypes (a–f)
of capsular strains of
H. influenzae, type b
causes serious chest
infections and appears
to be associated with
GBS
Anti-GM1 (AMAN) and
GQ1b (MFS)
[42,57–62]
GBS following
immunization with the
H. influenzae type b
conjugate vaccine
LOS from some type b
strains have been
shown to bear
ganglioside-like
molecules
Salmonella
species
1% of patients with
typhoid fever
developed GBS
AIDP, MFS, and
BBE
It is unclear whether
molecular mimicry plays
a role in Salmonella-
related GBS
GBS related to enteric
fever caused by
Salmonella Typhi
(typhoid fever) or
Salmonella Paratyphi
(paratyphoid fever)
Anti-GQ1b (BBE) [63–67]
Viral
  CMV 0.6–2.2 cases per 1000
persons
AIDP (up to 70%),
AMSAN, AMAN
(7%), and MFS
(6%)
The roles of anti-
ganglioside antibodies,
cellular immune
responses, and viral
replication are not yet
established
Serological evidence of
primary CMV infection
Anti-GM2 (IgM), more
closely associated with
primary CMV infection
than with GBS
[57,68–75]
Younger, female,
sensory
symptoms, and
facial palsy
T cell-mediated immune
response to neural
antigens
Anti-GalNAc-GD1a, GM1,
GM3, GD2, GD3, GT1b,
and GT1a
(Continued )
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Table 2. (Continued).
Agent Epidemiology
Subphenotype(s)
association
Physiopathological
mechanism Pathogen characteristics
Anti-gangliosides
antibodies References
GBS associated
with CMV
infection after
transplantation
Possible association
between viral
replication and sensory
defects
Molecular mimicry
Antibodies against
moesin, a component
of the ezrin–radixin–
moesin cytoplasmic
complex in Schwann 
cell microvilli that
surround the nodal
axolemma (not
replicated)
  EBV Large population studies
on the incidence of EBV
reactivation and GBS
are lacking
AIDP, AMSAN,
AMAN, and BBE
Immunological (anti-GQ1b
antibodies) mechanism
induced by infection
Acute EBV infection: IgM
and IgG antibodies
against VCA and the
absence of antibodies
to EBNA
Anti-GQ1b, GM1, and
GM3
[37,68,75–
79]
GBS associated
with EBV
infection after
transplantation
Disturb the regulatory
mechanisms that
normally inhibit latent
autoimmunity against
peripheral nerve
antigens rather than
providing a specific
autoimmune antigenic
stimulus
  VZV Risk of developing GBS
18.7-times greater
GBS Molecular mimicry: scarce
data regarding possible
structural mimicry
between VZV and the
molecules of human
peripheral nerves
More likely to have had
a recent infectious
event
Anti-GM1 (IgM) and GD-1
(IgM)
[37,80,[81]
Mainly in the
case of latent
infection
reactivation
Only 1% of antecedent
infections
Short latency
period between
rash onset and
the
development of
neurological
symptoms
HZ could play a
pathogenic role in
triggering GBS
GBS might be associated
with recent infectious
events of pathogens
other than VZV
Fewer than 50 cases
reported
Poor clinical
prognosis
Directly related to
autoimmune-mediated
responses initiated by
the VZV reactivation
Coinfection with
different strains of
pathogen can be
found
Aberrant immunological
status of the host
Imbalance of helper and
suppressor lymphocytes
Influenza virus   Four to  seven cases per
100,000 cases of
influenza
AMAN, AMSAN,
AIDP, and MFS
Influenza virus does not
share structural
homologies with known
gangliosides
Influenza A (H1N1),
influenza B virus
Anti-GD1b, GM1, GD1a,
Gal-C, GM3 (H1N1
vaccination), GQ1b
(MFS)
[68,82–91]
15-fold increased risk of
developing GBS
The mechanisms linking
influenza virus and GBS
are poorly understood
and probably relate to
increased risk of
secondary infection
18% had antecedent
influenza-like illness
and 3.5% had
serological evidence of
recent infection
GBS after seasonal and
2009 H1N1 monovalent
influenza vaccines 
a
  HIV GBS is a well  known but
rare complication of
primary HIV infection
AIDP, AMAN and
MFS
Immune mechanisms
poorly understood
GBS often develops in
early HIV and
Anti-GM1 [92–102]
Increased susceptibility to
infection, direct action
of HIV on nerves, and
generation of  myelin-
specific antibodies
sometimes at the time of
seroconversion and is
only rarely seen in
full-blown AIDS
Elevated titers of IgG
antibodies against
sulfatide, which is a
major
glycosphingolipid in
the myelin sheath
(significance in disease
pathogenesis
questionable)
(Continued )
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note that AID  P-associated Wallerian-like degenerationAQ7 occurs
mainly in the epi  perinerium of nerve trunks, as is the case in
175 P2-induced EANAQ8 , thus suggesting a pathogenic role for trans-
perineurial blood flow dysfunction in endoneurial ische-
mia [151].
C. jejuni induces the unbalance of Th1/Th2/Th17/Treg and
cytokines that is crucial for the development of GBS [14].
180Upregulation of Th1 cytokines in the early disease course
may be associated with immune-mediated disease progres-
sion due to neuronal inflammation, but upregulation of Th2
Table 2. (Continued).
Agent Epidemiology
Subphenotype(s)
association
Physiopathological
mechanism Pathogen characteristics
Anti-gangliosides
antibodies References
CD4+ T cell-mediated
cellular immunity
appears to play a role in
the pathogenesis of
GBS
GBS has also been
reported during
immune
reconstitution
following highly
active antiretroviral
therapy
  DENV Largest GBS-DENV
outbreak ever reported:
New Caledonia (2012–
2013)
AMAN, AIDP,
AMSAN, and
MFS
Molecular mimicry Serotypes (DENV 1–4) Anti-GD1b [103–118]
GBS is reported
during the
recovery phase
of illness
T cells produce cytokines
and chemokines which
open the BBB allowing
antibodies to enter and
Schwann cells to attack
Dengue nonstructural
protein 1 antibody
(anti-NS1) produced
after dengue infection
could be responsible
for the  cross-reactivity
to endothelial cell
There are a few cases of
GBS following dengue
infection (about 20
cases)
Oligosymptomatic
dengue
infection
(underestimates
prevalence of
GBS)
Activated T cells could
cross the vascular
endothelium (BBB) and
recognize an antigen in
the endoneural
compartment
GBS accounted for 30% of
the neurological
manifestations of
dengue infection
Proinflammatory
substances that
participate in immune
response to DENV such
as TNF, complement,
interleukins may have
important role in the
pathogenesis
  CHIKV Incidence per 10
6: up 22%
from baselineAQ5 (3.3),
Réunion Island
AIDP
GBS associated
with CHIKV
infection has
been rarely
reported yet
Tropism for brain tissue
  has been validated in
several mouse models
of CHIK neuroinfection
The presence of CSF
abnormalities and
CHIK-specific IgM
intrathecal synthesis
  was highly suggestive
of CHIK-induced
pathology in the
nervous system
Not reported [119–126]
The incidence rate of GBS
increased 22% in 2006
(26/787,000, persons)
Neurological
symptoms
started during
the invasion
phase prior to
seroconversion
Disseminated acute CHIKV
infection previous to
GBS development
Genomic products of
CHIKV in serum and
CSF are negative
GBS incidence was
increased four- to
nine  fold during
2014–2015 (French
Polynesia), suggesting a
link to CHIKV infection
  ZIKV 2.4  /10,000 ZIKV infections AMAN A causal relationship
between ZIKV and
neurological
complications is very
likely due to molecular
mimicry mechanism
  Neutralizing antibodies
against ZIKV
Anti-glycolipid antibodies:
anti-GA1, GM1, GM2,
GD1a, GD1b, and GQ1b
[41,127–
139]Incidence was 20-fold
higher than expected
during the time
coinciding with the
ZIKV epidemic in French
Polynesia
 
aThe estimated attributable risk of vaccine-related GBS in the adult population was just under one case per 100,000 vaccinations. Major nervous system gangliosides
include GM1, GM2, GD1a, GD1b, GT1a, GT1b, and GQ1b  .
AIDP: acute inflammatory demyelinating polyneuropathy  ; AMAN: acute motor axonal neuropathy  ; AMSAN: acute motor  sensory axonal neuropathy  ; BBB: blood–brain
barrier  ; BBE: Bickerstaff  brain s  tem encephalitis  ; CSF: cerebrospinal fluid  ; EBNA: antibodies against the EBV nuclear antigen complex  ; Gal-C: galactocerebroside  ; GBS:
Guillain–Barré  syndrome  ; LOS: lipo  oligosaccharide  ; MFS: Miller-Fisher syndrome  ; VCA: viral capsid antigen; EBV: Epstein–Barr virus; VZV: varicella-zoster virus; HIV:
human immunodeficiency virus; DENV: dengue virus; CHIKV: chikungunya virus; ZIKV: Zika virus; CMV: cytomegalovirus; TNF: tumor necrosis factor; Ig:
immunoglobulinAQ6 .
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immune response during the later phase aids recovery from
the disease [152]. In addition, Th17 also plays a pathogenic
185 role, and elevated circulating Th22 cells are correlated with
severity of disease, but not with GBS subphenotypes [153].
Th17 and Th22 cells of GBS patients at acute phase could
express an appropriate cytokine profile, like interleukin (IL)-
17, IL-22, and others (IL-6 and tumor necrosis factor  -α), which
190 can enhance the inflammatory and autoimmune response and
conduce to the development of GBS [153].
In the pathogenesis of AMAN, the early changes include
the lengthening of the node of Ranvier with myelin distortion
while overlying macrophages invade the space between
195 Schwann cell and the axon leaving the internodal myelin
sheath and Schwann cytoplasm intact. These changes may
be initially reversible, thus explaining the rapid recovery of
some patients [44]. The more rapid recovery observed in some
cases suggested that AMAN is associated with a block of
200 axonal conduction or axon terminal degeneration [154]. This
assumption has been challenged by the experimental evi-
dence shown by the preserved neuromuscular transmission
at axonal-stimulating single-fiber electromyography in AMAN,
thus supporting that transmission may be impaired in the
205 motor terminal axons proximal to the neuromuscular junction
[155]. Patients with AMAN manifest little demyelination or
lymphocytic inflammation but demonstrate the presence of
immunoglobulin G (IgG) and the complement activation pro-
duct C3d bound to the axolemma of motor fibers, and in
210 severe cases, IgG and C3d were found within periaxonal
space of the myelinated internodes [149].
Serum antiganglioside antibodies represent a major player
in the induction and perpetuation of GBS pathology.
Gangliosides are sialic acid containing subgroup of glyco-
215 sphingolipids with N-acetylneuraminic acid linked to an oligo-
saccharide core portion which is expressed on cell surface
[156]. Major nervous system gangliosides include GM1, GM2,
GD1a, GD1b, GT1a, GT1b, and GQIb, with specific localizations
at immunohistochemistry of peripheral nerves, as in the case
220 of GD1a in motor fibers and GD1b in large dorsal root ganglia
[154] and are illustrated in Table 3. Conversely, the GQ1b
epitope is predominant in oculomotor, trochlear, and abdu-
cens nerves [156], and Kusu  noki and colleagues demonstrated
that large neurons in dorsal ganglia had localization of GQ1b
225 epitope which could explain ataxia associated with opthalmo-
plegia seen in MFS [157]. GQ1b, GT1a, and GD1b mainly
localize in the extraocular muscles and limb muscle spindles
but are scarcely represented in the limb and axial muscle
neuromuscular junctions [157,158]. Anti-GQ1b antibodies
230 cross-react with GT1a and GD1b, thus explaining the paralytic
effects observed in the MFS in limited groups of muscles.
Kaida et al. described antibodies that are specific for a new
conformational epitope formed by two gangliosides such as
GD1a/GD1b or GQIb/GM1 ganglioside complexes with antibo-
235 dies associated with severe GBS requiring artificial ventilation
[159]. Bickerstaff’s brain stem encephalitis, characterized by
acute ophthalmoplegia, ataxia, and drowsiness, shares some
similar features with MFS including a prior C. jejuni infection
and positive serum  anti-GQ1b IgG antibody [160]. The phar-
240 yngeal–cervical–brachial weakness is associated with anti-
GT1a IgG with or without GQ1b reactivity [161]. Authors
from Japan reported the molecular mimicry of the lipopoly-
saccharide of C. jejuni with the GM1 ganglioside from a patient
with GBS  and with GQ1b from patients with MFS [148]. The
245AMAN subphenotype of GBS is associated with serum anti-
body to ganglioside GM1 in 64%, GM1b in 66%, GD1a in 45%,
and GalNac-GD1a in 33% of cases. Furthermore, 90% of
patients with MFS have serum antibodies to GQ1b, while the
AIDP subphenotype is frequently seronegative [4,150,162]. C.
250jejuni isolated from patients with GBS and   MFS frequently
express ganglioside mimics in their lipopolysaccharides, thus
possibly inducing antiganglioside antibodies and neurological
symptoms, while the heterogeneity in the LPS AQ9structure also
determines the specificity of the anti-glycolipid response [149].
255Specific C. jejuni strains have a set of polymorphic genes and
enzymes that can alter ganglioside-mimicking lipooligosac-
charide outer core [44], and only a subset of C. jejuni strains
contain lipo  polysaccharide that mimic gangliosides in periph-
eral nerves.
2605. Clinical subphenotypes
The clinical array of GBS varies widely from pure sensory [163]
to autonomic variants [164], but these classifications have
been challenged by recent reports, as will be discussed in
detail. AIDP and AMAN are the most common GBS subpheno-
265types. Other variants include MFS, AMSAN, Bickerstaff brain
stem encephalitis, and pharyngeal–cervical–brachial weakness
(the main characteristics are listed in Table 4). AIDP is some-
times mistaken for AMAN if conventional electrodiagnostic
data  are applied as patients with AMAN have a rapidly rever-
270sible conduction block or slowing evident on sequential stu-
dies, but numerous issues remain open, suggesting that AIDP
may be overestimated and AMAN underestimated. Such con-
duction blocks disappear with no electrophysiologic evidence
of remyelination in patients with AMAN [45]. Cranial nerve
275involvement is less frequent in AMAN compared to AIDP
[165]. The disease progression  in terms of muscle weakness
differs between AMAN and AIDP, being more rapid and with
an earlier peak in AMAN with a variable recovery pattern [166].
Table 3. Serum antibodies directed against specific gangliosides and the loca-
lization of the antigens in Guillain–Barré syndrome and subphenotypes [154–
158].
Ganglioside Localization Clinical association
GQ1b Oculomotor nerve Miller-Fisher syndrome
Trochlear nerve Bickerstaff’s brain  stem encephalitis
Abducens nerve Acute ataxic neuropathy (without
opthalmoplegia)
Dorsal root ganglion Acute ophthalmoparesis (without
ataxia)
Muscle spindle
GD1b Dorsal root ganglion Sensory ataxic GBS
Muscle spindle
GM1,
GD1a,
Myelinated axons in
both motor
AMAN
GalNac-
GD1a,
and sensory nerves AMSAN
Gm1b
GT1a, Glossopharyngeal nerve Pharyngeal–cervical–brachial
weakness
GQ1b Vagus nerve
GBS: Guillain–Barré  syndrome  ; AMAN: acute motor axonal neuropathy  ; AMSAN:
acute motor  sensory axonal neuropathy.
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An irreversible conduction block is associated with slow recov-
280 ery and extensive axonal degeneration at the nerve roots with
poor recovery.
AIDP is characterized by autonomic dysfunction such as
hyperhidrosis and fluctuations in blood pressure  ; autonomic
dysfunction is uncommon in AMAN [167]. In general terms,
285 AMAN has been classically addressed as the pure motor form
of GBS with no sensory deficits and the acute motor sensory
axonal neuropathy is the most severe variant [168], but more
recent pathology reported that pure motor GBS is associated
with primary demyelination mainly involving the ventral roots
290[169,170], while 11% of patients with AIDP manifest a pure
motor GBS [21].
The MFS is associated with ophthalmoplegia, ataxia, and
areflexia in its classical form but may present in a limited form
with bilateral internal ophthalmoplegia or bilateral abducent
295nerve palsies. In the majority (up to 76%) of patients, MFS is
anticipated by an upper respiratory tract infection [171] and
associated with serum GQ1b antibody in approximately 90%
of cases. Patients with pharyngeal–cervical–brachial weakness
manifest with symptoms affecting the oropharyngeal, neck,
300and shoulder muscles  and have detectable serum anti-GT1a
antibody as GT1a is expressed predominantly in the glosso-
pharyngeal nerve and vagal nerves [172].
6. Diagnosis
Diagnostic criteria for GBS were first published in 1981 and
305later modified in 1990 [173,174]  to include features that make
the diagnosis more or less likely (Table 5) and to verify the
proposed rise in the frequency of GBS following vaccination
for swine influenza virus. New diagnostic classification has
been recently published in order to enable neurologists and
310non-neurologists to diagnose GBS and all its variants using a
simple yet all-inclusive classification system [175]. The typical
onset of GBS is characterized by the rapidly progressive, sym-
metrical weakness of limbs usually reaching its maximum
severity within 4 weeks [150]. In a large cohort of patients, a
315monophasic course was observed in 95% of patients, and 97%
of patients had reached the clinical nadir by 4 weeks  and 80%
by 2 weeks [176]. An atypical presentation of GBS, such as
paraparesis, is seen in approximately 8% of patients which can
persist up to 6 months, while 9% of patients have normal
320tendon reflexes in the weak arms and 2% in the weak legs
Table 4. Clinical subphenotypes and major features in Guillain–Barré syndrome
(GBS) [45–168].
GBS subphenotype Clinical features Notes
AIDP Multifocal patchy Most common in
Demyelination Europe/USA
Secondary axonal
degeneration in
85–90% of cases
small percentage of
patients
  Association with CMV 
and
Autonomic
dysfunction
EBV infections.
Common includingAQ10
HTN,
No AB association
  hyperhidrosis, and
blood pressure
fluctuation.
Cranial nerve palsy
Frequent sensory loss
  AMAN Cranial nerves rarely
affected
Ab to GM1a, GD1a
Tendon reflexes might
be preserved
Preceding infection is
C.
or exaggerated in 20%
of patients.
jejuni
Progression more
rapid and recovery
5  –10% of GBS in USA
longer compared to
AIDP
30  –65% of GBS
patients in Asia,
South America, and
Central
America
Acute motor and sensory
axonal neuropathy 
Severe form of AMAN Antibody to GM 1a and
GD1a ganglioside
  MFS Ophthalmoplegia,
ataxia, areflexia
Anti-GQ1b, anti-GT1a
No impaired
consciousness
Antibodies in 90% of
Incomplete MFS patients.
Acute
ophthalmoparesis
Preceding infections
include
without C. jejuni, Haemophilus
ataxia   influenzae
Acute ataxic
neuropathy
(no
ophthalmoparesis)
Bickerstaff brain
stem
Ophthalmoplegic
ataxia
GQ1b antibodies
brain Areflexia GT 1a antibodies
stem Absence of limb
encephalitis Weakness
Impaired
consciousness
Pharyngeal– Oropharyngeal neck
and arm
Anti-GT1a antibodies
  cervical– weakness Anti-GQ 1b IgG
antibodies
  brachial Absence of leg
weakness
weakness
CMV: cytomegalovirus  ; EBV: Epstein–Barr virus; Ab: antibody; AIDP: acute inflam-
matory demyelinating polyradiculoneuropathy; AMAN: acute motor axonal
neuropathy; MFS: Miller-Fisher syndromeAQ11 .
Table 5. Diagnostic criteria for Guillain–Barré syndrome [174–175].
Features necessary for the diagnosis of GBS:
● Progressive weakness in both arms and both legs
● Areflexia
Features strongly supporting the diagnosis of GBS:
● Progression of symptoms over days to 4 weeks
● Relative symmetry of symptoms
● Mild sensory symptoms or signs
● Autonomic dysfunction
● Cranial nerve involvement, especially bilateral weakness of facial muscles
● Absence of fever at onset
● Typical electrodiagnostic features
● High concentration of protein in cerebrospinal fluid, with fewer cells than
10  × 10/l
● Recovery beginning 2–4 weeks after progression ceases
Features making the diagnosis of GBS less likely:
● Bladder or bowel dysfunction at onset
● Persistent bladder or bowel dysfunction
● Sharp spinal cord sensory level
● Marked persistent asymmetry of weakness
● Increased number of mononuclear cells in CSF (>50 cells/μl)
● Severe pulmonary dysfunction with limited limb weakness at onset
● Fever at onset of neurological symptoms
● Polymorphonuclear cells in CSF
CSF: cerebrospinal fluid  ; GBS: Guillain–Barré  syndrome.
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at presentation [176]. Severe respiratory muscle weakness
necessitating ventilatory support develops in 10–30% of
patients.
MFS is diagnosed in patients with opthalmoplegia, ataxia,
325 and areflexia but may also present with incomplete forms
without ataxia and in association with serum anti-GQ1b anti-
body. Different incomplete forms of MFS are known as ataxic
GBS to include ataxia without opthalmoplegia and negative
Romberg test and acute sensory ataxic neuropathy with ataxia
330 and a positive Romberg test but no opthalmoplegia.
Paraparetic GBS is another uncommon and localized variant
in which patients develop isolated flaccid lower limb weakness
and absent deep tendon reflexes in lower limbs but without
neurological findings in the upper limbs [176]. The facial mus-
335 cle weakness with paresthesias may also appear as a GBS
variant coined in the absence of opthalmoplegia or limb
weakness, to be distinguished from Lyme disease, sarcoidosis,
and bilateral Bell palsy by the presence of serum antiganglio-
side antibodies. In general terms, atypical and incomplete
340 presentations of GBS should be included in the diagnostic
work-up of patients with new onset peripheral symptoms
and addressed with a careful history and serological panel.
A CSF analysis is frequently obtained in the differential
diagnosis of GBS, and the Brighton Collaboration criteria for
345 GBS and MFS include a cell count in the CSF lower than 50
cells/μl [177]. The albumin-cytological dissociation is a combi-
nation of elevated protein level and normal CSF cell count and
is observed in only   two-thirds of cases, as elevated protein
concentration is dependent on the timing of the lumbar
350 puncture. One large Dutch cohort of patients manifested ele-
vated CSF protein in 53% of cases when puncture was per-
formed in the first 3 days after onset of weakness and
increased to 80% after  7 days. A CSF cell count between 5
and 50 cells/μl was found in 15% of patients [177]. In an Asian
355 cohort, there was a lower prevalence of elevated CSF protein
concentration (55%) and a higher proportion of mild pleocy-
tosis up to 26% [178]. Therefore, normal CSF protein concen-
tration in the first week of weakness does not rule out GBS as
the sensitivity is as low as 50%. Only in a subgroup of cases,
360 CSF cell count is higher than 50 cells/μl, and differential diag-
noses include Lyme disease or  human immunodeficiency virus
(HIV)-related radiculitis [178].
Neurophysiological studies are frequently used in the diag-
nostic process of suspect GBS cases, and nerve conduction
365 studies are helpful to identify the subphenotype of GBS type
and exclude disorders that may mimic GBS. AIDP, AMAN, and
AMSAN are difficult to distinguish based only on clinical
grounds; electrophysiology is the key test. Nerve conduction
studies can be normal in nearly  one-third of patients when
370 done during the first 4 days, but the absence of F waves or a
prolonged F wave latency  is frequently observed, especially in
the lower limbs. Selective lesions in proximal nerve trunks may
explain the discrepancy between nerve conduction and the
established paralysis, as elegantly illustrated in electrophysio-
375 logical [179] and ultrasonographic [180,181] studies of the
ventral spinal nerves in AIDP and AMAN/AMSAN. The sensory
nerve conduction study of sural nerve is normal in greater
proportion of patients [182]. Nerve conduction studies sug-
gestive of demyelination in early AIDP are nonspecific and
380may occur in disorders that mimic the acute-stage GBS, includ-
ing acute myelopathy or critical illness polyneuropathy, but
more specific finding suggestive of early demyelinating GBS  is
the presence of a spared normal sural sensory nerve action
potential with abnormal ulnar sensory nerve action potential
385in one retrospective study [183]. Patients with normal EMG AQ12
have significantly milder weakness at the lowest peak of dis-
ease progression compared to patients with abnormal nerve
conduction study [176]. Almost 85% of patients with GBS have
abnormal nerve conduction studies after 3 weeks and includ-
390ing additional nerves in the study improves sensitivity. Motor
conduction slowing exceeding 30% below the lower limit of
normal, prolongation of motor distal latency of >150% of
upper limit of normal, and prolongation of F wave latency
over 120% in  two nerves  are specific for primary demyelina-
395tion [184]. The compound muscle action potential  is reduced
<80% of the lower limit of the normal range in at least two
nerves without signs of demyelination in AMAN. However,
patients with AMAN may present reversible conduction failure
likely derived from an impaired conduction at the  nodes of
400Ranvier due to antibodies to gangliosides and can be falsely
diagnosed as having AIDP instead of AMAN due to nerve
conduction features suggesting demyelination [185]. Nerve
conduction studies need to be interpreted with caution espe-
cially when performed early in the disease course, and some-
405times, serial studies need to be performed to improve
sensitivity, and reversible conduction failure has to be taken
into account and most importantly should not delay treat-
ment. Almost 40% of GBS cases did not meet criteria for one
of the defined subphenotypes of GBS [176].
4107. Differential diagnosis
Careful history, physical examination, CSF analysis, nerve con-
duction studies, and imaging studies help differentiate GBS and
its subphenotypes from other mimics. These include infectious
causes, leptomeningeal malignancy, and disorders of the neu-
415romuscular junction (Table 6). GBS manifests a monophasic
course in 90% of cases, but 10% of patients develop recurrent
or relapsing form. A course not showing improvements after
8 weeks is not typical for GBS, and chronic inflammatory
demyelinating neuropathy  needs to be ruled out, particularly
420since patients with this latter condition may mimic GBS at the
early stages of progression [186]. Poliomyelitis should be con-
sidered in unvaccinated individuals with travel to endemic
areas, and   non-polio enteroviruses may cause acute flaccid
paraparesis with high mortality. West Nile virus and herpes
425simplex virus can cause extensive necrotizing myelopathy
[187]. Herpes, hepatitis A, and rabies viruses may cause trans-
verse myelitis manifesting with back pain with sharp sensory
disturbances and changes at MRI based. AQ13Elevated CSF lympho-
cytes with painful asymmetric polyradiculoneuropathy that
430occurs several months after a tick bite could be due to Lyme
disease. Gadolinium MRI allows to discriminate the paraparetic
variants of GBS from cauda equina syndrome and lumbosacral
plexopathy. Findings of nerve root enhancement support  a
diagnosis of GBS. Diphtheria can cause neuropathy involving
435either cranial or peripheral nerves, which is demyelinating in
nature as opposed to other acute peripheral neuropathies
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which are of axonal type [187]. Different from virus-induced
transverse myelitis, Listeria, Mycobacteria, and Lyme disease
may associate with brain stem encephalitis that, however, may
440 also be based on autoimmune mechanisms and mimic MFS and
Bickerstaff brain stem encephalitis. The Bickerstaff brain stem
encephalitis may mimic Wernicke’s encephalopathy from thia-
mine deficiency in alcoholism or other causes of dietary imbal-
ance such as major gastrointestinal surgery [188]. HIV infection
445 may directly involve spinal cord, nerve root, and peripheral
nerves, and opportunistic infections with cytomegalovirus,
Epstein–Barr virus, and  varicella-zoster virus can cause acute
flaccid paralysis.
8. Treatment
450 Patients with GBS need a multidisciplinary approach, which
includes careful monitoring of vital capacity, prevention of
infections, monitoring for possible autonomic dysfunction,
physical therapy, and rehabilitation.
Approximately  one-third of patients with GBS need to be
455 admitted to the intensive care unit because of respiratory
failure, dysautonomia, or   medical complications [189].
Adequate ventilation relies on the triad of adequate inspira-
tory effort, effective expiratory force, and ability to protect the
airway. The decision to intubate the patient with GBS is based
460 on clinical and paraclinical evidence of impending or overt
respiratory failure, including impaired mentation, air hunger,
increased respiratory rate, the inability to count on one breath
to 20, forehead sweating, staccato speech, paradoxical respira-
tion, inability to lift the head from the bed, shoulder weakness,
465and signs of bulbar muscle weakness [189]. Chronic ventilatory
failure should be suspected by a history of fatigue, lethargy,
difficulty concentrating, poor sleep and daytime somnolence,
and morning headache (indicating  hypercapnia) [190].
Prednisolone or intravenous methylprednisolone treatment
470in GBS patients did not improve patient outcomes [191,192].
Plasmapheresis and IVIg are the only known effective treat-
ments for GBS. Plasmapheresis was found to be most effective
in GBS cases who received treatment within the first 2 weeks
of disease onset and who are unable to walk [193]. Two
475plasma exchanges were found to ameliorate mildly affected
GBS cases who were able to walk. Patients with severe GBS
who need mechanical ventilator had to undergo at least  four
plasma exchange sessions to improve outcomes [194]. In a
randomized controlled trial, IVIg given daily for 5 consecutive
480days were as effective as   five sessions of plasma exchange
started within 14 days [195]. IVIg inhibits the binding of auto-
antibodies to GQ1b and also complement activation by anti-
GQ1b in a mouse model [196]. IVIg is preferred in young
children over plasma exchange where it can be technically
485difficult and also patients with cardiovascular instability, given
large volume shifts that occur with plasma exchange. Patients
with GBS who received IVIg showed significant pharmacoki-
netic variation, and patients with low rise in serum IgG
  2 weeks after treatment have a more severe clinical course
490and poor outcomes at   6 months after   standard-dose treat-
ment independent of other prognostic factors [197]. IVIg ther-
apy did not affect recovery outcomes in patients with MFS,
and excellent recovery from ophthalmoplegia and ataxia was
noted in patients who did not receive plasmapheresis or IVIg
495treatment at the end of  1 year [198]. A double-blind, placebo-
controlled randomized trial showed no additional benefit
when combining methylprednisolone and IVIg [199]. Adverse
prognostic indicators include previous diarrhea, older age,
disease severity, and rapid disease onset [7].
500Pain is a common symptom in GBS patients, occurring in
up to 50% of all GBS patients, and should be diagnosed and
treated promptly [200]. Another priority to consider is mon-
itoring nutritional status.
Death or severe residual disability has varied widely with
505rates between 1%  and 18% despite immunotherapy [7,201  ].
Death results from pneumonia, sepsis, adult respiratory dis-
tress syndrome, and autonomic dysfunction [201], and data
are awaited from an ongoing prospective international multi-
center observational trial assessed whether a second dose of
510IVIg (I-SID-GBS AQ16) improved outcomes in poor-prognosis cases.
Erythropoietin has been associated with the amelioration of
nerve regeneration/repair with reversal of inhibitory effects of
anti-ganglioside antibodies on nerve repair in an animal
model [191]. Eculizumab is a humanized monoclonal antibody
515against the complement protein C5 which appeared protec-
tive against complement-mediated motor neuropathy and
respiratory paralysis in a mouse model [192], and phase II
clinical trials are currently recruiting patients in Scotland and
Japan. Clinical studies are still lacking on the use of
Table 6. Conditions mimicking Guillain–Barré syndrome  to be included in the
differential diagnosis  . 
Peripheral neuropathy
● Chronic inflammatory demyelinating polyneuropathy
● Lead, thallium, and arsenic poisoning
● Acute intermittent porphyria
● Critical illness polyneuropathy (associated with use of  high-dose  intravenous
steroids)
● Tick paralysis
● Metabolic disturbances of serum potassium, phosphate, magnesium, and
glucose
● Severe vitamin B1 deficiency
● Puffer fish poisoning
Neuromuscular junction disorders
● Myasthenia gravis
● Lambert–Eaton myasthenic syndrome
● Botulism
Spinal cord involvement
● Transverse myelitis (CMV, herpes simplex virus, Epstein–Barr virus, and  var-
icella-zoster virus)
● Anterior spinal artery occlusion
● Epidural abscess
Anterior horn cell involvement
● Poliomyelitis  and  non-polio enterovirus (enterovirus 71)
● West Nile virus, herpes simplex virus, CMV, and  varicella-zoster virus
● Rabies virus  and HIV
Muscle disorders
● Acute myositis (postinfectious can be sec to influenza AAQ14 )
● Acute hypokalemic periodic paralysis (often familial)
● Thyrotoxic periodic paralysis (more common in Asians and Hispanics)
Brain stem stroke
Brain stem encephalitis
● Listeriosis, tuberculosis, brucellosis, JC virus, and toxoplasmosis
● Multiple sclerosis, sarcoidosis, and systemic lupus erythematosus
Wernicke encephalopathy
Adapted from Ref. [187].
CMV: cytomegalovirus  ; HIV: human immunodeficiency virusAQ15 .
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520 erythropoietin or eculizumab. New and more effective treat-
ments are required to improve the prognosis.
9. Expert commentary
GBS encompasses numerous common paradigms of autoim-
mune and chronic inflammatory diseases, including but not
525 limited to the specific serum autoantibodies, the infectious
trigger, and the response to immunosuppressants, similar to
other conditions [202]. First described almost a century ago by
three French neurologists, GBS is an uncommon disease (with
incidence rates ranging between 0.81 and 1.89  [median 1.11  ]
530 cases per 100,000  person-years) but is the most frequent cause
of acute flaccid symmetrical weakness of the limbs and areflexia
following the polio era. Different from other autoimmune or
chronic inflammatory diseases, GBS is more prevalent in men
(male to female ratio of 1  :5). The syndrome typically appears
535 with a rapidly progressive, symmetrical weakness of limbs
usually reaching its peak within a month and respiratory or
gastrointestinal infections precede the symptoms within
6 weeks in the majority of patients [203,204]. GBS is strongly
linked to Campylobacter infection, but less than 0.1% of infec-
540 tions result in the syndrome. The most recent outbreak of Zika
virus infection raises concerns also for GBS as cases have been
reported within a Zika and Dengue fever epidemics in French
Polynesia and South America. Diagnostic criteria include fea-
tures that make the diagnosis more or less likely and were first
545 published in 1981 to be modified recently, but clinical suspicion
and physician awareness remain the limiting factors of the
diagnostic approach. The AMAN and the AIDP represent the
most common clinical subphenotypes along with the more rare
MFS, AMSAN, Bickerstaff brain stem encephalitis, and pharyn-
550 geal–cervical–brachial weakness. Besides the activation of
macrophages and T cells, serum antibodies are associated
with GBS being directed at gangliosides, sialic acid containing
subgroup of glycosphingolipids with N-acetylneuraminic acid
linked to an oligosaccharide core portion. Nervous system
555 gangliosides include GM1, GM2, GD1a, GD1b, GT1a, GT1b, and
GQIb, with specific localizations by immunohistochemistry pos-
sibly predicting the associated clinical phenotype. GBS results in
death or severe disability in near 20% of cases despite immu-
notherapy, which is represented by plasmapheresis and IVIg  s
560 which remain the cornerstone of the medical management.
Cumulatively, GBS is a heterogeneous condition with numerous
subphenotypes, and advances have been made over the past
20 years on the understanding of GBS immunopathogenesis 
and localization of ganglioside epitopes by immunohistochem-
565 ical methods. Ultimately, we are convinced that GBS, similar to
other inflammatory diseases, is the result of a permissive
genetic background on which environmental factors, including
infections, vaccination, and the influence of aging, lead to
disease onset and the natural history of disease [203–210].
570 10. Five-year view
Further research efforts are needed to identify GBS biomarkers
to help in the early diagnosis,  predict progression, and initiate
adequate treatment. Similar to what observed in other auto-
immune conditions [202,211], serum autoantibodies currently
575represent the only option for diagnostic and prognostic pur-
poses, but our understanding is limited by the relative rarity of
the disease. New powerful tools should be used in GBS to
determine additional serum autoantibodies, including protein
and RNA immunoprecipitation. Alternative research directions
580should be sought for a better understanding of GBS patho-
genesis, including the collection of large multicenter series of
patients, including twins [212], or the study of sex-related
factors [213] via epigenetics [214–217]. Ultimately, we are
convinced AQ17that the enormous number of biotechnological
585drugs, i.e., monoclonal antibodies  and small molecules, may
prove useful also in GBS by tackling pivotal pathogenesis  of
effector inflammatory mechanisms [218,219].
Key issues
● Guillain-Barré syndrome was first described almost a cen-
590tury ago by three French neurologists and remains the
most frequent cause of acute flaccid symmetrical weakness
of the limbs and areflexia;
● Guillain-Barré syndrome yearly incidence ranges between
0.81 and 1.89 (median 1.11) cases per 100,000 person;
595● Guillain-Barré syndrome is more prevalent in men by 50%;
● Guillain-Barré syndrome onset is observed with a rapidly
progressive, symmetrical weakness of limbs;
● Guillain-Barré syndrome follows respiratory or gastrointest-
inal infections within 6 weeks in the majority of patients,
600often by Campylobacter;
● The most recent outbreak of Zika virus infection raises
concerns also for Guillain-Barré syndrome as cases have
been reported within Zika and Dengue fever epidemics;
● Most frequently observed subphenotypes include the acute
605motor axonal neuropathy (AMAN) and the acute inflamma-
tory demyelinating polyradiculoneuropathy (AIDP);
● Rare forms are represented by Miller-Fisher syndrome
(MFS), acute motor and sensory axonal neuropathy
(AMSAN), Bickerstaff brain stem encephalitis, and pharyn-
610geal-cervical-brachial weakness;
● Serum autoantibodies are detected against gangliosides
mainly GM1, GM2, GD1a, GD1b, GT1a, GT1b and GQIb;
● Despite treatment, Guillain-Barré syndrome mortality or
severe disability occur in near 20%;
615● Immunotherapy includes high-dose steroids, plasmapher-
esis, and intravenous immunoglobulins.
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